Trial Profile
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for PAH for Subjects in the PULSE-PAH-006 and PULSE-PAH-004 Studies Who Continue to Need iNO Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Bellerophon Therapeutics
- 07 Feb 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Feb 2022).
- 17 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 17 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2023.